Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||-0.01%||78.32||0.7%||$1640.63m|
|JNJ||Johnson & Johnson||0.72%||161.26||0.7%||$1027.09m|
|BMY||Bristol-Myers Squibb Co.||1.11%||58.34||1.0%||$691.66m|
|LLY||Eli Lilly & Co.||0.55%||237.98||1.1%||$629.67m|
|AVIR||Atea Pharmaceuticals, Inc.||-2.89%||39.28||0.3%||$121.41m|
|CRVS||Corvus Pharmaceuticals, Inc.||-3.51%||4.95||0.7%||$109.87m|
|NVO||Novo Nordisk A/S||1.89%||102.34||0.1%||$90.55m|
|RPRX||Royalty Pharma Plc||3.59%||38.39||0.1%||$87.06m|
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian SchÃ¶nharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.